Compare Ascendis Pharma A/S (ASND) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Otis Worldwide Corp — how do they compare? Ascendis Pharma A/S trades at $257.44 (market cap $16.67B), while Otis Worldwide Corp trades at $73.57 (market cap $27.80B). The key difference: Otis Worldwide Corp is the larger of the two by market cap, and Otis Worldwide Corp pays a 2.41% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | OTIS | |
|---|---|---|
Market Cap | $16.67B | $27.80B |
Sector | Health | Industrials |
52-Week High | $277.18 | $93.62 |
52-Week Low | $189.74 | $69.34 |
Enterprise Value | $17.04B | $35.84B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Otis Worldwide (OTIS) trades at $72.87, down 1.51% over 24 hours, with a neutral technical signal and bearish moving averages. Recent Q2 2026 earnings beat estimates but saw margin pressures and full-year guidance cuts. The company maintains strong service segment growth, with 9% organic sales increase, while facing headwinds in new equipment demand and labor costs. Valuation metrics show a P/E of 18.78 and P/S of 1.91, below historical averages after a 19% year-to-date decline.
Outlook is mixed: analyst consensus targets $92.50 with 47% buy ratings, but near-term risks include persistent margin compression and weak equipment sales. Long-term potential hinges on service margin expansion and modernization backlog execution, though investor sentiment remains cautious amid earnings misses and macroeconomic volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
